401 related articles for article (PubMed ID: 30463996)
1.
Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Afatinib and Lapatinib Against
Nakata S; Fujita M; Nakanishi H
Anticancer Res; 2019 Nov; 39(11):5927-5932. PubMed ID: 31704817
[TBL] [Abstract][Full Text] [Related]
3. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.
Kwak EL; Ahronian LG; Siravegna G; Mussolin B; Borger DR; Godfrey JT; Jessop NA; Clark JW; Blaszkowsky LS; Ryan DP; Lennerz JK; Iafrate AJ; Bardelli A; Hong TS; Corcoran RB
Cancer Discov; 2015 Dec; 5(12):1271-81. PubMed ID: 26432108
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
5. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.
Hjortland GO; Meza-Zepeda LA; Beiske K; Ree AH; Tveito S; Hoifodt H; Bohler PJ; Hole KH; Myklebost O; Fodstad O; Smeland S; Hovig E
BMC Cancer; 2011 Oct; 11():455. PubMed ID: 22014070
[TBL] [Abstract][Full Text] [Related]
6. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.
Kim J; Fox C; Peng S; Pusung M; Pectasides E; Matthee E; Hong YS; Do IG; Jang J; Thorner AR; Van Hummelen P; Rustgi AK; Wong KK; Zhou Z; Tang P; Kim KM; Lee J; Bass AJ
J Clin Invest; 2014 Dec; 124(12):5145-58. PubMed ID: 25401468
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
Torigoe H; Shien K; Takeda T; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Sakaguchi M; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Cancer Sci; 2018 May; 109(5):1493-1502. PubMed ID: 29532558
[TBL] [Abstract][Full Text] [Related]
8. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma.
Gambardella V; Fleitas T; Tarazona N; Cejalvo JM; Gimeno-Valiente F; Martinez-Ciarpaglini C; Huerta M; Roselló S; Castillo J; Roda D; Cervantes A
Ann Oncol; 2019 Aug; 30(8):1254-1264. PubMed ID: 31046106
[TBL] [Abstract][Full Text] [Related]
9. Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.
Apicella M; Migliore C; Capelôa T; Menegon S; Cargnelutti M; Degiuli M; Sapino A; Sottile A; Sarotto I; Casorzo L; Cassoni P; De Simone M; Comoglio PM; Marsoni S; Corso S; Giordano S
Oncogene; 2017 Mar; 36(9):1200-1210. PubMed ID: 27524418
[TBL] [Abstract][Full Text] [Related]
10. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
[TBL] [Abstract][Full Text] [Related]
12. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.
Jørgensen JT
World J Gastroenterol; 2014 Apr; 20(16):4526-35. PubMed ID: 24782605
[TBL] [Abstract][Full Text] [Related]
13. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.
Maron SB; Chatila W; Walch H; Chou JF; Ceglia N; Ptashkin R; Do RKG; Paroder V; Pandit-Taskar N; Lewis JS; Biachi De Castria T; Sabwa S; Socolow F; Feder L; Thomas J; Schulze I; Kim K; Elzein A; Bojilova V; Zatzman M; Bhanot U; Nagy RJ; Lee J; Simmons M; Segal M; Ku GY; Ilson DH; Capanu M; Hechtman JF; Merghoub T; Shah S; Schultz N; Solit DB; Janjigian YY
Clin Cancer Res; 2023 Sep; 29(18):3633-3640. PubMed ID: 37406106
[TBL] [Abstract][Full Text] [Related]
14.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
15. MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells.
Ebert K; Mattes J; Kunzke T; Zwingenberger G; Luber B
PLoS One; 2019; 14(9):e0223225. PubMed ID: 31557260
[TBL] [Abstract][Full Text] [Related]
16. Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer.
Shu S; Iimori M; Nakanishi R; Jogo T; Saeki H; Oki E; Maehara Y
In Vivo; 2018; 32(6):1491-1498. PubMed ID: 30348707
[TBL] [Abstract][Full Text] [Related]
17. ERBB2 amplifications in esophageal adenocarcinoma.
Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
Yoshioka T; Shien K; Takeda T; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Soh J; Fujiwara T; Toyooka S
Cancer Sci; 2019 Aug; 110(8):2549-2557. PubMed ID: 31162771
[TBL] [Abstract][Full Text] [Related]
19. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
20. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]